Acknowledgement
This study was funded by Daiichi Sankyo, Boston Scientific, Terumo, Biotronik, Qualitech Korea, and Dio. This research was partially supported by a grant from Seoul National University Hospital (Research ID: 03-2021-0030). The funders of this study had no role in study design, collection of data and data analysis, or writing of the manuscript.
References
- Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS guidelines on myocardial revascularization. Eur Heart J 2019;40:87-165. https://doi.org/10.1093/eurheartj/ehy394
- Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57. https://doi.org/10.1056/NEJMoa0904327
- Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-15. https://doi.org/10.1056/NEJMoa0706482
- Kang J, Park KW, Ki YJ, et al. Development and validation of an ischemic and bleeding risk evaluation tool in East Asian patients receiving percutaneous coronary intervention. Thromb Haemost 2019;119:1182-93. https://doi.org/10.1055/s-0039-1688792
- Kang J, Park KW, Palmerini T, et al. Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs. Thromb Haemost 2019;119:149-62. https://doi.org/10.1055/s-0038-1676545
- Ki YJ, Kang J, Park J, et al. Efficacy and safety of long-term and short-term dual antiplatelet therapy: a meta-analysis of comparison between Asians and non-Asians. J Clin Med 2020;9:652.
- Valgimigli M, Costa F, Lokhnygina Y, et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 2017;38:804-10.
- Costa F, van Klaveren D, James S, et al. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet 2017;389:1025-34. https://doi.org/10.1016/S0140-6736(17)30397-5
- Kim HS, Kang J, Hwang D, et al. Prasugrel-based de-escalation of dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (HOST-REDUCEPOLYTECH-ACS): an open-label, multicentre, non-inferiority randomised trial. Lancet 2020;396:1079-89. https://doi.org/10.1016/S0140-6736(20)31791-8
- Franchi F, Rollini F, Angiolillo DJ. Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol 2017;14:361-79. https://doi.org/10.1038/nrcardio.2017.18
- Lee JM, Jung JH, Park KW, et al. Harmonizing Optimal Strategy for Treatment of coronary artery diseases--comparison of REDUCtion of prasugrEl dose or POLYmer TECHnology in ACS patients (HOST-REDUCE-POLYTECH-ACS RCT): study protocol for a randomized controlled trial. Trials 2015;16:409.
- Kim HS, Kang J, Hwang D, et al. Durable polymer versus biodegradable polymer drug-eluting stents after percutaneous coronary intervention in patients with acute coronary syndrome: the HOST-REDUCE-POLYTECH-ACS trial. Circulation 2021;143:1081-91. https://doi.org/10.1161/CIRCULATIONAHA.120.051700
- Garcia-Garcia HM, McFadden EP, Farb A, et al. Standardized end point definitions for coronary intervention trials: the Academic Research Consortium-2 consensus document. Circulation 2018;137:2635-50. https://doi.org/10.1161/CIRCULATIONAHA.117.029289
- Montalescot G, Wiviott SD, Braunwald E, et al. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 2009;373:723-31. https://doi.org/10.1016/S0140-6736(09)60441-4
- Steg PG, James S, Harrington RA, et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: a Platelet Inhibition and Patient Outcomes (PLATO) trial subgroup analysis. Circulation 2010;122:2131-41. https://doi.org/10.1161/CIRCULATIONAHA.109.927582
- Udell JA, Braunwald E, Antman EM, Murphy SA, Montalescot G, Wiviott SD. Prasugrel versus clopidogrel in patients with ST-segment elevation myocardial infarction according to timing of percutaneous coronary intervention: a TRITON-TIMI 38 subgroup analysis (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38). JACC Cardiovasc Interv 2014;7:604-12. https://doi.org/10.1016/j.jcin.2014.01.160
- Velders MA, Abtan J, Angiolillo DJ, et al. Safety and efficacy of ticagrelor and clopidogrel in primary percutaneous coronary intervention. Heart 2016;102:617-25. https://doi.org/10.1136/heartjnl-2015-308963
- Kim BK, Hong SJ, Cho YH, et al. Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial. JAMA 2020;323:2407-16. https://doi.org/10.1001/jama.2020.7580
- Lee SJ, Cho JY, Kim BK, et al. Ticagrelor monotherapy versus ticagrelor with aspirin in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2021;14:431-40. https://doi.org/10.1016/j.jcin.2020.11.036
- Kupka D, Sibbing D. De-escalation of P2Y12 receptor inhibitor therapy after acute coronary syndromes in patients undergoing percutaneous coronary intervention. Korean Circ J 2018;48:863-72. https://doi.org/10.4070/kcj.2018.0255
- Lee HS, Park KW, Kang J, Han JK, Kim HS. De-escalation of prasugrel results in higher percentage of patients within optimal range of platelet reactivity. Thromb Haemost. 2021 [Epub ahead of print].
- Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med 2019;381:2032-42. https://doi.org/10.1056/NEJMoa1908419
- Hahn JY, Song YB, Oh JH, et al. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. Lancet 2018;391:1274-84. https://doi.org/10.1016/S0140-6736(18)30493-8
- Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med 2015;372:1791-800. https://doi.org/10.1056/NEJMoa1500857